BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock Overview
NASDAQ:BBOT - KYG4444H1011 - Common Stock
BBOT Key Statistics, Chart & Performance
The current stock price of BBOT is 9.3 USD.
About BBOT
Company Profile
Helix Acquisition Corp. II operates as a blank check company. The company is headquartered in Boston, Massachusetts. The company went IPO on 2024-02-09. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company has entered into a business combination agreement with TheRas, Inc., doing business as BridgeBio Oncology Therapeutics. Upon closing of the transaction, the combined company will be renamed BridgeBio Oncology Therapeutics, Inc.
Company Info
BRIDGEBIO ONCOLOGY THERAPEUT
C/O Cormorant Asset Management, Lp, 200 Clarendon Street, 52Nd Floor
Boston MASSACHUSETTS US
Employees: 0
Phone: 18577020377
BRIDGEBIO ONCOLOGY THERAPEUT / BBOT FAQ
What is the stock price of BRIDGEBIO ONCOLOGY THERAPEUT today?
The current stock price of BBOT is 9.3 USD. The price decreased by -2.97% in the last trading session.
What is the ticker symbol for BRIDGEBIO ONCOLOGY THERAPEUT stock?
The exchange symbol of BRIDGEBIO ONCOLOGY THERAPEUT is BBOT and it is listed on the Nasdaq exchange.
On which exchange is BBOT stock listed?
BBOT stock is listed on the Nasdaq exchange.
What is BRIDGEBIO ONCOLOGY THERAPEUT worth?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) has a market capitalization of 736.56M USD. This makes BBOT a Small Cap stock.
How many employees does BRIDGEBIO ONCOLOGY THERAPEUT have?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) currently has 0 employees.
What are the support and resistance levels for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) has a resistance level at 9.72. Check the full technical report for a detailed analysis of BBOT support and resistance levels.
Should I buy BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BBOT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BBOT, evaluating the profitability, health, valuation and growth aspects
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Sales and EPS estimates to see what analysts future expectations are.
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock Chart to make your own analysis
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Latest news and press-releases to stay up to date.
Does BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock pay dividends?
BBOT does not pay a dividend.
What is the Price/Earnings (PE) ratio of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT)?
The PE ratio for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 46.5. This is based on the reported non-GAAP earnings per share of 0.2 and the current share price of 9.3 USD. Check the full fundamental report for a full analysis of the valuation metrics for BBOT.
BBOT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BBOT.
BBOT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BBOT. The financial health of BBOT is average, but there are quite some concerns on its profitability.
BBOT Financial Highlights
Over the last trailing twelve months BBOT reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 17.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 2.39% | ||
| ROE | 2.49% | ||
| Debt/Equity | 0 |